New radiation combo may let some rectal cancer patients skip surgery
NCT ID NCT04677413
First seen May 02, 2026 · Last updated Jun 23, 2026 · Updated 12 times
Summary
This early-phase trial is testing a new way of giving radiation therapy (ultra-fractionated, short course) along with standard chemotherapy for people with locally advanced rectal cancer. The goal is to see if this combination can shrink the tumor enough to avoid surgery. The study will enroll 27 adults with stage T3-4 or node-positive rectal cancer who have not had prior treatment. The main focus is on safety and finding the highest dose that does not cause severe side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UT Southwestern Medical Center
RECRUITINGDallas, Texas, 75390-8849, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ultra-fractionated radiotherapy with FOLFOX or CAPOX chemotherapy
What this could lead to
If successful, this approach could allow some patients with advanced rectal cancer to avoid surgery by achieving a complete response with radiation and chemo alone.
What could go wrong
This is a very early phase 1 trial with only 27 participants, focused on safety and finding the right dose. It is not yet known if it will be effective or widely applicable, and there is a risk of serious gastrointestinal side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.